Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871032 | 0.77 | PARP1 (0.42) | AHRPARP1GPR84TRPA1ADRB1 | |
| SCHEMBL1876842 | 0.77 | TYR (0.40) | P4HBAHRUSP2GAAALOX15 | |
| SCHEMBL1565897 | 0.74 | AHR (0.52) | AHRPARP1GPR84TRPA1ADRB1 | |
| SCHEMBL31005469 | 0.74 | P2RX7 (0.38) | P4HBAHRUSP2GAAALOX15 | |
| SCHEMBL13425079 | 0.74 | AHR (0.38) | AHRPARP1GPR84TRPA1ADRB1 | |
| SCHEMBL31431597 | 0.74 | AHR (0.38) | AHRPARP1GPR84TRPA1MAPK1 | |
| SCHEMBL7448671 | 0.74 | RHEB (0.47) | AHRPARP1GPR84RHEB | |
| SCHEMBL2985458 | 0.74 | AHR (0.38) | AHRPARP1GPR84TRPA1MAPK1 | |
| SCHEMBL2503153 | 0.74 | RHEB (0.40) | P4HBAHRUSP2GAAALOX15 | |
| SCHEMBL4388854 | 0.74 | AHR (0.47) | P4HBAHRUSP2GAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115701440-A | Polyimide composite film, preparation method thereof and electronic equipment | 华为技术有限公司 | 2023-02-10 | — | — | CN | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | claimed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | claimed |
| EP-1553097-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | claimed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| CN-100360505-C | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | CN | claimed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | claimed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| CN-1597667-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2005-03-23 | — | — | CN | claimed |
| US-20240173340-A1 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2024-05-30 | — | — | US | disclosed |
| US-20240122950-A1 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2024-04-18 | — | — | US | disclosed |
| US-11918594-B2 | Multi-substituent psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2024-03-05 | — | — | US | disclosed |
| EP-4291549-A1 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-12-20 | — | — | EP | disclosed |
| CN-117222622-A | Polysubstituted galectin derivative and use method thereof | 恩维瑞克生物科学加拿大公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| CN-1346271-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA UK LTD (SE) | 2002-04-24 | — | — | CN | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173340-A1 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | CNR2, CNR1, HTR1B | P4HB 2271/4885AHR 1603/4885USP2 3320/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | P4HB 4463/4885AHR 2545/4885USP2 4604/4885 |
| US-11918594-B2 | Multi-substituent psilocybin derivatives and methods of using | CNR2, CNR1, HTR1B | P4HB 2271/4885AHR 1603/4885USP2 3320/4885 |
| US-20240122950-A1 | MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USING | CNR2, CNR1, HTR1B | P4HB 2271/4885AHR 1603/4885USP2 3320/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | P4HB 2688/4885AHR 2883/4885USP2 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.